Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | MicrobiomeTrials← Back to trialsNCT04335682
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2021-08-17Est. Completion: 2025-09-01
Enrollment target: 111 participants Locations- University of California - San Francisco at Mount Zion, San Francisco, California, United States
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- University of Kansas Cancer Center, Fairway, Kansas, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- University of Oklahoma, Oklahoma City, Oklahoma, United States
- Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
Anatomic Stage IV Breast Cancer AJCC v8Breast CarcinomaHER2-Negative Breast CarcinomaHormone Receptor-Positive Breast Carcinoma
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a me…
Fairbanks, United StatesEst. completion Jul 31, 2027
Metastatic Castration-resistant Prostate Cancer
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abira…
Goodyear, United StatesEst. completion Jan 7, 2030
Anal Basaloid CarcinomaAnal Canal Cloacogenic CarcinomaAnal Canal Squamous Cell CarcinomaAnal Margin Squamous Cell CarcinomaStage I Anal Cancer AJCC v8Stage IIA Anal Cancer AJCC v8
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison…
Birmingham, United StatesEst. completion Dec 31, 2029